Experimental treatment significantly slows progression of a fatal brain disease in women during clinical trial
Researchers at Tel Aviv University found that the drug Davunetide may significantly slow the progression of progressive supranuclear palsy (PSP) in women. The study suggests that sex-specific responses to neurodegenerative treatments are critical for future clinical trials.
Why it matters
This finding could lead to more effective, personalized treatments for a previously untreatable fatal brain disease.
edited by Gaby Clark , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Disease Time Progression (52 Weeks) Per Patient: Protection by Davunetide in Women and Increasing Effects on the FDA-Recommended PSPRS-10 Individual Outcome Measures. Credit: Molecular Psychiatry (2026). DOI: 10.1038/s41380-026-03709-x Researchers at Tel Aviv University have presented new findings indicating that the experimental drug Davunetide may significantly slow the progression of progressive supranuclear palsy (PSP) in women, who exhibited a markedly different response to treatment than men. These results reinforce the need for sex-specific medicine in neurodegenerative diseases.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in